Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
New new contracts, summarized for you
No login, no app to check — it comes to you
See who's moving and how much in your market
Roche Partners With COUR in Autoimmune Collaboration Potentially Worth Over $900M
Contract Type
partnership
GrindelwaldOtherBiotechnologyDescription
Roche's Genentech and COUR Pharmaceuticals have announced a collaboration to develop and commercialize treatments for an autoimmune disease. The deal includes an upfront payment of $40 million to COUR, with potential milestone payments exceeding $900 million, as well as tiered royalties for COUR. The collaboration will involve COUR handling preclinical development and technical transfer of manufacturing, while Genentech will manage clinical development, regulatory filing, and commercialization.